Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

News provided by

Jul 24, 2012, 05:33 ET

NEW YORK, July 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
http://www.reportlinker.com/p0606218/Neuroendocrine-Carcinoma-Therapeutics---Pipeline-Assessment-and-Market-Forecast-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Summary

GlobalData, the industry analysis specialist, has released its new report, "Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019". The report is an essential source of information and analysis on the global neuroendocrine carcinoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019. The high growth is primarily attributed to the advent of approved drugs, Sutent (sunitinib) and Afinitor (everolimus), in the major markets. The expected launch of promising drugs in the forecast period will drive the market. The promising drugs to be launched include: Avastin (bevacizumab) and Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) for Gastrointestinal (GI) carcinoid and pancreatic Neuroendocrine Tumors (NETs), pasireotide (SOM 230), and Somatuline (lanreotide acetate) Autogel/Depot for GI carcinoids NETs. These factors will accelerate the growth of the neuroendocrine carcinoma therapeutics market.

Scope

- Annualized data on the seven key neuroendocrine carcinoma markets (the US, France, Germany, Italy, Spain, the UK and Japan) revenue data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data showing a split across the different phases, mechanisms of action being developed and emerging trends in the market. Pipeline candidates fall under the following mechanisms of action: Somatostatin analogues and Vascular Endothelial Growth Factor (VEGF) inhibitors, insulin-like growth factor-1 receptor (IGFR-1) inhibitors, tyrosine kinase inhibitor (TKI) and Smoothened (Smo) inhibitor.
- Analysis of the current and future competition in the global neuroendocrine carcinoma market. Key market players covered are Novartis AG, Roche, the Eli Lilly & Company, Callisto Pharmaceuticals, Molecular Insight pharmaceuticals, Advanced Accelerator Applications S.A, Roche, Ipsen and Amgen Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, market characterization, and unmet needs and their implications for the neuroendocrine carcinoma therapeutics market.
- Analysis of key recent licensing and partnership agreements in the neuroendocrine carcinoma market.

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global neuroendocrine carcinoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global neuroendocrine carcinoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What is the next big thing in the global neuroendocrine carcinoma market landscape? Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Neuroendocrine Carcinoma Therapeutics - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.3 Risk Factors 10
2.4 Etiology 11
2.5 Symptoms 11
2.6 Diagnosis 12
2.7 Staging 16
2.8 Treatment and Management Pattern 19
2.8.1 Treatment Algorithm 19
2.8.2 Treatment for GI Carcinoid Tumors 19
2.8.3 Treatment for Pancreatic NETs/Islet Cell Tumor 21
2.9 Referral Pathway for GEP-NETs 22
2.10 GlobalData Pipeline Report Guidance 24
3 Neuroendocrine Carcinoma Therapeutics- Market Characterization 25
3.1 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Global 25
3.2 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) – Global 27
3.3 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – the US 29
3.4 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the US 30
3.5 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) –the UK 31
3.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK 32
3.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France 33
3.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France 34
3.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany 35
3.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany 36
3.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy 37
3.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy 38
3.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain 39
3.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain 40
3.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan 41
3.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan 42
3.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market 43
3.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market 43
3.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market 43
3.18 Key Events Impacting the Future Market 44
3.19 Opportunity and Unmet Need 44
3.19.1 Gastrointestinal carcinoid (NETs) 45
3.19.2 Pancreatic NETs 45
3.20 Key Takeaway 46
4 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment 47
4.1 Overview 47
4.1.1 Strategic Competitor Assessment 47
4.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma 49
4.2.1 Afinitor (everolimus, RAD001) 49
4.2.2 Sutent (sunitinib) 50
4.2.3 Sandostatin LAR (octreotide acetate) 51
4.3 Key Takeaway 51
5 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 52
5.1 Overview 52
5.2 Strategic Pipeline Assessment 52
5.3 Analysis by Phase of Development 53
5.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline 53
5.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline 54
5.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline 54
5.3.4 Neuroendocrine Carcinoma Therapeutics - Preclinical Pipeline 54
5.4 Neuroendocrine Carcinoma Therapeutics- Clinical Pipeline by Mechanism of Action 55
5.5 Technology Trends Analytic Framework 55
5.6 Neuroendocrine Carcinoma Therapeutics - Key Late Stage Pipeline Drugs in Clinical Development 58
5.7 Molecule Profile for Key Late Stage Pipeline Drugs under Clinical Development 58
5.7.1 Avastin (bevacizumab) 58
5.7.2 Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) 59
5.7.3 Paseriotide (SOM 230) 60
5.7.4 Somatuline Autogel (lanreotide acetate) 61
5.8 Key Takeaway 61
6 Neuroendocrine Carcinoma Therapeutics - Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Prominent Sponsors 65
6.5 Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 67
7 Neuroendocrine Carcinoma Therapeutics- Strategic Assessment 68
7.1 Future Market Competition Scenario 68
8 Neuroendocrine Carcinoma Therapeutics - Future Players 70
8.1 Introduction 70
8.2 Company Profiles for the Promising Drugs 70
8.2.1 Advanced Accelerator Applications S.A 70
8.2.2 Novartis AG 71
8.2.3 F. Hoffmann-La Roche 73
8.2.4 Ipsen SA 74
8.3 Other Companies in the Neuroendocrine Carcinoma Therapeutics Market 76
9 Neuroendocrine Carcinoma Therapeutics- Licensing and Partnership Deals 77
10 Neuroendocrine Carcinoma Therapeutics - Appendix 79
10.1 Market Definitions 79
10.2 Abbreviations 79
10.3 Methodology 80
10.3.1 Coverage 81
10.3.2 Secondary Research 81
10.3.3 Forecasting 81
10.3.4 Primary Research 83
10.3.5 Expert Panel Validation 84
10.4 Contact Us 84
10.5 Disclaimer 84
10.6 Bibliography 84

List of Tables

Table 1: GEP-NETs WHO Classification 7
Table 2:GEP-NETs Classification 8
Table 3: Historical Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 9
Table 4: Forecast Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 10
Table 5: Symptoms of Pancreatic NETs/Islet Cell Tumors 12
Table 6:Diagnosis Techniques by Site of Origin for GI Carcinoid Tumors 14
Table 7:Diagnosis Tests for Different Types of Functioning Pancreatic Neuroendocrine Tumors 15
Table 8:TNM Classification of Stomach Carcinoid Tumors 16
Table 9:TNM Classification of Duodenum Carcinoid Tumors 17
Table 10:TNM Staging of Appendiceal Carcinoid Tumors 17
Table 11:TNM Classification of Pancreatic Neuroendocrine Tumors 18
Table 12:TNM Staging for Pancreatic Neuroendocrine Tumors 18
Table 13:Chemotherapy Regimens in GEP-NETs Carcinoma 22
Table 14: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006–2011 25
Table 15: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Market Forecast ($m), 2011-2019 28
Table 16:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006–2011 29
Table 17: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 30
Table 18:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006–2011 31
Table 19: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 32
Table 20:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue($m), 2006–2011 33
Table 21: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 34
Table 22:Neuroendocrine Carcinoma Therapeutics Market,Germany, Revenue ($m), 2006–2011 35
Table 23: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 36
Table 24:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue($m), 2006–2011 37
Table 25: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 38
Table 26:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006–2011 39
Table 27:Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 40
Table 28:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006–2011 41
Table 29: Neuroendocrine Carcinoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 42
Table 30:Neuroendocrine Carcinoma Therapeutics – Phase III Pipeline, 2012 53
Table 31:Neuroendocrine Carcinoma Therapeutics – Phase II Pipeline, 2012 54
Table 32:Neuroendocrine Carcinoma Therapeutics – Phase I Clinical Pipeline, 2012 54
Table 33:Neuroendocrine Carcinoma Therapeutics – Preclinical Pipeline, 2012 54
Table 34: Neuroendocrine Carcinoma Therapeutics –Phase III Promising Drugs in Clinical Development 58
Table 35:Adverse events of Bevacizumab and Peginterferon alfa-2b 59
Table 36:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Region/Country, 2012 62
Table 37:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012 63
Table 38:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012 64
Table 39:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Overall Sponsors, 2012 65
Table 40: Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Prominent Sponsors, 2012 66
Table 41: Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012 67
Table 42: Advanced Accelerator Applications S.A. – Neuroendocrine Carcinoma Pipeline Product, 2012 71
Table 43:Novartis AG – Oncology Pipeline Products, 2012 72
Table 44:Novartis AG – Neuroendocrine Carcinoma Pipeline Product, 2012 72
Table 45:F. Hoffmann-La Roche- Oncology Pipeline Products, 2012 74
Table 46:F. Hoffmann-La Roche – Neuroendocrine Carcinoma Pipeline Product, 2012 74
Table 47:Ipsen SA- Oncology Pipeline Products, 2012 75
Table 48:Ipsen SA- Neuroendocrine Carcinoma Pipeline Product, 2012 75
Table 49:Neuroendocrine Carcinoma Therapeutics – Other Future Players, 2012 76
Table 50:Neuroendocrine Carcinoma Therapeutics, Global, Deals ($m), 2012 77

List of Figures

Figure 1: Patient Share of Neuroendocrine Carcinoma* in the Seven Major Markets, 2011 9
Figure 2:Treatment Algorithm for GEP-NETs 19
Figure 3:Referral Pathway for GEP-NETs 23
Figure 4: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011 25
Figure 5:Neuroendocrine Carcinoma Therapeutics , Market Share (%), 2011 26
Figure 6: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Forecast ($m), 2011-2019 27
Figure 7:Neuroendocrine Carcinoma Therapeutics, Market Share (%), 2019 28
Figure 8:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006-2011 29
Figure 9: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019 30
Figure 10:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006-2011 31
Figure 11: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019 32
Figure 12:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue ($m), 2006-2011 33
Figure 13: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019 34
Figure 14:Neuroendocrine Carcinoma Therapeutics Market, Germany, Revenue ($m), 2006-2011 35
Figure 15: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 36
Figure 16:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue ($m), 2006-2011 37
Figure 17: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 38
Figure 18:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006-2011 39
Figure 19: Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 40
Figure 20:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006-2011 41
Figure 21: Neuroendocrine Carcinoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 42
Figure 22:Neuroendocrine Carcinoma Therapeutics – Drivers and Barriers, 2012 44
Figure 23:Opportunities and Unmet Need in the GI Carcinoid NETs Therapeutics Market 45
Figure 24:Opportunities and Unmet Need in Pancreatic NETs Therapeutics Market 46
Figure 25: Strategic Competitor Assessment of the Major Marketed Products in GI Carcinoid NETs, 2012 48
Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Pancreatic NETs, 2012 49
Figure 27: Neuroendocrine Carcinoma Therapeutics Pipeline by Phase of Clinical Development, 2012 53
Figure 28: Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Mechanism of Action, 2012 55
Figure 29: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline, 2012 56
Figure 30: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline – Description, 2012 57
Figure 31:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Region/Country, 2012 62
Figure 32:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012 63
Figure 33:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012 64
Figure 34:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Overall Sponsors, 2012 65
Figure 35: Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Prominent Sponsors, 2012 66
Figure 36:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012 67
Figure 37:GI Carcinoids NETs Therapeutics – Implications for Future Market Competition, 2012 68
Figure 38:Pancreatic NETs Therapeutics – Implications for Future Market Competition, 2012 69
Figure 39:Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Company, 2012 70
Figure 40- GlobalData Market Forecasting Model 83

Companies mentioned
Advanced Accelerator Applications S.A
Novartis AG
F. Hoffmann-La Roche
Ipsen SA